International Journal of Cancer Management

Published by: Kowsar

Effect of Emodin on Expression of VEGF-A and VEGFR_2 Genes in Human Breast Carcinoma MCF-7 Cell

Fatemeh Cheshmi 1 , Faranak Kazerouni 1 , * , Mir Davood Omrani 2 , Ali Rahimipour 1 , Mehrnoosh Shanaki 3 , Nasrin Dehghan -Nayeri 4 , Ommolbanin Younesian 1 and Maryam Rezapour Kalkhoran 1
Authors Information
1 Department of Laboratory Medicine, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Proteomics Research Center, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: July 2017, 10 (7); e8095
  • Published Online: July 31, 2017
  • Article Type: Research Article
  • Received: August 7, 2016
  • Revised: October 16, 2016
  • Accepted: July 15, 2017
  • DOI: 10.5812/ijcm.8095

To Cite: Cheshmi F, Kazerouni F, Omrani M D, Rahimipour A, Shanaki M, et al. Effect of Emodin on Expression of VEGF-A and VEGFR_2 Genes in Human Breast Carcinoma MCF-7 Cell, Int J Cancer Manag. 2017 ; 10(7):e8095. doi: 10.5812/ijcm.8095.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 2013; 328(2): 318-24[DOI][PubMed]
  • 2. Longatto Filho A, Lopes JM, Schmitt FC. Angiogenesis and breast cancer. Journal of oncology. 2010;
  • 3. Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. Taylor & Francis. 2010;
  • 4. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014; 2(12): 123[DOI][PubMed]
  • 5. Kristensen TB, Knutsson ML, Wehland M, Laursen BE, Grimm D, Warnke E, et al. Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci. 2014; 15(12): 23024-41[DOI][PubMed]
  • 6. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347): 298-307[DOI][PubMed]
  • 7. Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Aspects Med. 2011; 32(2): 71-87[DOI][PubMed]
  • 8. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8): 579-91[DOI][PubMed]
  • 9. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, et al. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer. 2006; 118(11): 2711-20[DOI][PubMed]
  • 10. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7(5): 359-71[DOI][PubMed]
  • 11. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci. 2006; 11: 818-29[PubMed]
  • 12. Chen YC, Shen SC, Lee WR, Hsu FL, Lin HY, Ko CH. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol. 2002; 64(12): 1713-24
  • 13. Su YT, Chang HL, Shyue SK, Hsu SL. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol. 2005; 70(2): 229-41[DOI][PubMed]
  • 14. Srinivas G, Anto RJ, Srinivas P, Vidhyalakshmi S, Senan VP, Karunagaran D. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur J Pharmacol. 2003; 473(2-3): 117-25[PubMed]
  • 15. Wei WT, Lin SZ, Liu DL, Wang ZH. The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). Oncol Rep. 2013; 30(6): 2555-62[DOI][PubMed]
  • 16. Lu Y, Zhang J, Qian J. The effect of emodin on VEGF receptors in human colon cancer cells. Cancer Biother Radiopharm. 2008; 23(2): 222-8[DOI][PubMed]
  • 17. Li WY, Chan RY, Yu PH, Chan SW. Emodin induces cytotoxic effect in human breast carcinoma MCF-7 cell through modulating the expression of apoptosis-related genes. Pharm Biol. 2013; 51(9): 1175-81[DOI][PubMed]
  • 18. Zu C, Zhang M, Xue H, Cai X, Zhao L, He A, et al. Emodin induces apoptosis of human breast cancer cells by modulating the expression of apoptosis-related genes. Oncol Lett. 2015; 10(5): 2919-24[DOI][PubMed]
  • 19. Yu Y, Cai W, Pei CG, Shao Y. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy. Biochem Biophys Res Commun. 2015; 458(4): 913-9[DOI][PubMed]
  • 20. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007; 27(5): 591-608[DOI][PubMed]
  • 21. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev. 2007; 27(5): 609-30[DOI][PubMed]
  • 22. Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, et al. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013; 341(2): 139-49[DOI][PubMed]
  • 23. Ren H, Zhu C, Li Z, Yang W, Song E. Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF. Int J Mol Sci. 2014; 15(9): 16936-48[DOI][PubMed]
  • 24. Wang Y, Yu H, Zhang J, Ge X, Gao J, Zhang Y, et al. Anti-tumor effect of emodin on gynecological cancer cells. Cell Oncol (Dordr). 2015; 38(5): 353-63[DOI][PubMed]
  • 25. Lin SZ, Wei WT, Chen H, Chen KJ, Tong HF, Wang ZH, et al. Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis. PLoS One. 2012; 7(8): 42146[DOI][PubMed]
  • 26. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat. 2003; 82(3): 147-54[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments